post COVID-19 condition

Subcutaneous Lidocaine-HP-β-CD: A Potential Disease-Modifying Breakthrough for Post-COVID Condition

A 36-week observational study demonstrates that subcutaneous lidocaine-HP-β-CD significantly improves physical and mental quality of life and reduces symptom burden in patients with post-COVID condition, offering a scalable, home-based ther

What, When and How to Measure Post COVID-19 Condition: The New Core Outcome Set for Clinical Trials